Please Wait
Applying Filters...
menu
    • menu
    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Olutasidenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 10,975Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rigel Publishes 5-Year Rezlidhia Data in R/R mIDH1 AML
    Rigel Publishes 5-Year Rezlidhia Data in R/R mIDH1 AML

    17 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-announces-publication-of-final-5-year-data-on-rezlidhia-olutasidenib-in-patients-with-rr-midh1-aml-in-the-journal-of-hematology--oncology-302616427.html

    PR NEWSWIRE
    17 Nov 2025
    Share Share
    Rigel Presents Five Studies at ASH Annual Meeting
    Rigel Presents Five Studies at ASH Annual Meeting

    03 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-announces-one-oral-and-four-poster-presentations-at-the-67th-american-society-of-hematology-annual-meeting-and-exposition-302602603.html

    PR NEWSWIRE
    03 Nov 2025
    Share Share
    Rigel Enrolls First Patient in Phase 1b/2 Trial of REZLIDHIA® in mIDH1 AML
    Rigel Enrolls First Patient in Phase 1b/2 Trial of REZLIDHIA® in mIDH1 AML

    05 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-announces-first-patient-enrolled-in-phase-1b2-triplet-therapy-trial-of-rezlidhia-olutasidenib-in-midh1-aml-302238788.html

    PR NEWSWIRE
    05 Sep 2024
    Share Share
    Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update
    Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update

    06 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-reports-second-quarter-2024-financial-results-and-provides-business-update-302215852.html

    PR NEWSWIRE
    06 Aug 2024
    Share Share
    Rigel Announces Publication of Data on REZLIDHIA in Post-Venetoclax Patients
    Rigel Announces Publication of Data on REZLIDHIA in Post-Venetoclax Patients

    04 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-announces-publication-of-data-on-rezlidhia-olutasidenib-in-post-venetoclax-patients-with-mutant-idh1-aml-in-leukemia--lymphoma-302107833.html

    PR NEWSWIRE
    04 Apr 2024
    Share Share
    Rigel Announces Collaboration with CONNECT to Conduct Phase 2 of Olutasidenib
    Rigel Announces Collaboration with CONNECT to Conduct Phase 2 of Olutasidenib

    04 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rigel-announces-collaboration-with-connect-to-conduct-a-phase-2-trial-of-olutasidenib-in-glioma-302026029.html

    PR NEWSWIRE
    04 Jan 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.